Источники.

1.	Guillebaud, J., Contraception: your questions answered, London, Churchill Livingstone, (revised edn) 1991, pp293-4.
2.	de Groot, R., Antibiotic Resistance in Haemophilus influenzae, Rotterdam, Erasmus University, 1991, p13.
3.	Lanza, O. and Kerkvliet, E., Ojo con los antidiarreicos: el abuso de antidiarreicos en America Latina, Montevideo, AIS/IOCU, 1991, pp35-40.
4.	Scott, H.D., Thacher-Renshaw, A., et al, «Physician reporting of adverse drug reactions: results of the Rhode Island Adverse Drug Reaction Reporting Project», Journal of the American Medical Association, Vol 263, No 13, 4 Apr 1990, pp1785-8.
5.	Garotta, F. and Messa, A., «Safety profile of ceftizoxime: an Italian experience on 14,007 patients», Journal of Chemotherapy, Vol 3 (suppl. no 2), 1991, рр36-8.
6.	Lexchin, J., «Adverse drug reactions: review of the Canadian literature», Canadian Family Physician, Vol 37, Jan 1991, pp109-18.
7.	Anon., «54,404 ADRs filed in US in 1987», Scrip, No 1318, 17 Jun 1988, p21; Kaur, N., «Overprescription: doctors profit, patients suffer», Utusan Konsumer, mid-Jan 1992, p5; Lexchin, op cit.
8.	Fletcher, A.P., «Spontaneous adverse drug reaction reporting vs event monitoring: a comparison», Journal of the Royal Society of Medicine, Vol 84, Jun 1991, pp341-4.
9.	IFPMA, IFPMA Code of Pharmaceutical Marketing Practices, Geneva, IFPMA, 1989, p4.
10.	Medawar, C., The Wrong Kind of Medicine?, London, Consumers’ Association and Hodder & Stoughton, 1984, pp45-6.
11.	Abrahams, P., «Discovering healthy profits», Financial Times, 10 Dec 1991, Section III, рIII.
12.	WHO, Clinical Pharmacological Evaluation in Drug Control, EUR/ICP/DSE 173, Copenhagen, WHO, 1993.
13.	Schwartz, H., «Improving the industry’s image», Scrip, No 1620/21, 29/31 May 1991, pp22-3.
14.	Anon., «Drug use problems in Latin America», Scrip, No 1683, 15 Jan 1992, p28.
15.	Anon., «Pharmaceutical misuse costs Iran $100 mill pa». Scrip, No 1787, 19 Jan 1993, p13.
16.	Fabricant, S.J. and Hirschhorn, N., «Deranged distribution, perverse prescription, unprotected use: the irrationality of pharmaceuticals in the developing world», Health Policy and Planning, Vol 2, No 3, 1987, pp204-13; WHO, The World Drug Situation, Geneva, WHO, 1988.
17.	Ballen, K., «America’s most admired corporations», Fortune, 10 Feb 1992, рр30-4.
18.	Anon., «US promotion criticised», Scrip, No 1577/8, 21/26 Dec 1990, pp16-17.
19.	Anon., «FDA’s drug promotion problems», Scrip, No 1389, 24 Feb 1989, p14.
20.	Anon., «FDA warns industry on promotion», Scrip, No 1611, 26 Apr 1991, p17.
21.	Chetley, A. and Mintzes, B. (eds), Promoting Health or Pushing Drugs?, Amsterdam, HAI, 1992, pp12-15.
22.	Health and Public Policy Committee of the American College of Physicians, «Improving medical education in therapeutics», Annals of Internal Medicine, Vol 108, No 1, Jan 1988, pp145-7.
23.	Grant, R., Which? Medicine, London, Consumers Association and Hodder & Stoughton, 1992, p58.
24.	Position paper entitled «Physicians and the Pharmaceutical Industry», quoted in: Schwartz, H., «Are pharmaceutical companies bribing doctors? - the Schwartz commentary», Scrip, No 1515, 18 May 1990, p22.
25.	Anon., «When drug labels cry wolf», The Economist, 12 Oct 1985, p96.
25a.	Ibid
26.	Steele, R.W. and Kearns, G.L., «Antimicrobial therapy for paediatric patients», Pediatric Clinics of North America, Vol 36, No 5, Oct 1989, pp1321-49.
27.	Lynn, M., The Billion Dollar Battle: Merck v Glaxo, London, Mandarin, 1992, p128.
28.	Anon., «Call for independent source of French drug information», Scrip, No 1500, 28 Mar 1990, p1.
29.	Anon., «US FDA criticises Praxis’promotion», Scrip, No 1609,19 Apr 1991, pl2; Anon., «FDA censures Bristol-Myers Squibb», Scrip, No 1592, 20 Feb 1991, p11; Anon., «Abbott»s US Hytrin campaign rejected», Scrip, No 1488, 14 Feb 1990, p17; Anon., «FDA criticises Lupron promotion», Scrip, No 1503, 6 Apr 1990, p17.
30.	Anon., «Effectiveness of UK pharma reps», Scrip, No 1596, 6 Mar 1991, p4.
31.	Safavi, K.T. and Hayward, R.A., «Choosing between apples and apples: Physicians’ choices of prescription drugs that have similar side effects and efficacies», Journal of General Internal Medicine, Vol 7, Jan/Feb 1992, pp32-7.
32.	Medawar, C., Power and Dependence, London, Social Audit, 1992; Lacey, R., The Complete Guide to Psychiatric Drugs, London, Ebury Press, 1991; Neill, J.R., «A social history of psychotropic drug advertisements», Social Science and Medicine, Vol 28, No 4, 1989, ррЗЗЗ-8; Toynbee, P., «The patients who get hooked on tranquillisers», Guardian, 25 Nov 1985, p10.
33.	Jackson, D.M. and Soothill, R., Is the Medicine Making You Ill?, North Ryde, Australia, Angus & Robertson, 1989, pp56-7.
34.	Comment made in а ВВС Radio 4 programme, File on Four, broadcast 11 June 1991
35.	Liss, R.H. and Batchelor, F.R., «Economic evaluations of antibiotic use and resistance - a perspective: report of Task Force 6», Reviews of Infectious Diseases, Vol 9 (Suppl. 3), May-Jun l987, ppS297-312.
36.	O'Reilly, В., «Drugmakers under attack», Fortune, 29 Jul 1991, pp108-18.
37.	Clark, E., The Want Makers, London, Coronet Books, 1989, p289.
38.	Cunliffe, P.W., «Drugs in the Third World» (letter to the editor), The Listener, 3 Oct 1985.
39.	Randall, Т., «Kennedy hearings say no more free lunch - or much else - from drug firms», Journal of the American Medical Association, Vol 265, No 4, 23/30 Jan 1991, pp440-2.
40.	Barral, E., Prospective et sante, No 36, Winter 1985/86, pp89-95, cited in WHO, 1988, op cit, pp38-9. See also: Anon., «10 years of NCE discovery analysed», Scrip, No 1062, 23 Dec 1985, pp20-1.
41.	Marsh, P., «Prescribing all the way to the bank», New Scientist, 18 Nov 1989, pp50-5.
42.	Brown, P., «A Caribbean banana lesson for the pharmaceutical industry», Scrip Magazine, No 10, Dec 1992/Jan 1993, pp3-4.
43.	Schwartz, H., «The pharmaceutical companies and their critics», International Health and Development, Mar/Apr 1989, pp24-7.
44.	Leisinger, K.M., Poverty, Sickness and Medicines: an unholy alliance?, Geneva, IFPMA, 1989, p21.
45.	Fresle, D., «How many drugs do we really need?», World Health, Mar-Apr 1992, p9.
46.	Laurence, D.R. and Bennett, P.N., Clinical Pharmacology, Edinburgh, Churchill Livingstone, (6th edn), 1987, p307.
47.	Nakajima, H., «How essential is an essential drugs policy?», World Health, Mar-Apr 1992, p3.

Дата добавления: 2015-07-17